By using this site, you agree to the Privacy Policy and Terms of Use.

CANCER IDENTIFICATION
Healthcare Technology August 22, 2022

Evolution of Biopsies in Cancer Identification

Healthcare Technology August 18, 2022

The Growth of Digital Health –

Biomarkers
Healthcare Pharma Technology August 9, 2022

Biomarkers & Their Increasingly Crucial Role

Tower B5, Office 101, Magarpatta SEZ Hadapsar, Pune-411013, India

+91 20 48598285

[email protected]

MarketsandMarkets Conferences > Blog > epigenetics
Healthcare News Pharma

Speaker Interview With Alfred Budillon FOR 4th Annual MarketsandMarkets Epigenetics Congress

London, UK July 30, 2019 – MarketsandMarkets recently interviewed Alfred Budillon, Chief Experimental Pharmacology Unit Department, Istituto Nazionale Tumori, Italy regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Dr. Budillon graduated in Medicine and passed the Specialty Certification in Oncology at University Federico II, Naples, Italy. […]

Read More
4th Annual MarketsandMarkets Epigenetics Congress Healthcare News Pharma

Speaker Interview With Gavin Reynolds For 4TH Annual MarketsandMarkets Epigenetics Congress

London, UK July 29, 2019 – MarketsandMarkets recently interviewed Gavin Reynolds, Professor Emeritus, Queen’s University Belfast, UK regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Gavin Reynolds is Honorary Professor at Sheffield Hallam University and Professor Emeritus, previously Chair of Neuroscience, at Queen’s University Belfast. […]

Read More
MarketsandMarkets Epigenetics Congress Healthcare News Pharma Uncategorized

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been […]

Read More